Avanos Medical, Inc. Provides Sales Guidance for the Fourth Quarter and Year Ended December 31, 2023 and Year Ending December 31, 2024
January 04, 2024 at 08:00 am EST
Share
Avanos Medical, Inc. provided sales guidance for the fourth quarter and year ended December 31, 2023 and year ending December 31, 2024. For the fourth quarter, the company expected net sales in the range of $170 million to $173 million, a decrease of approximately 6.5% to 4.5% compared to the same period in 2022.
For the year ended December 31, 2023, the company anticipated to be in the range of $670 million to $673 million.
For the year ending December 31, 2024, the company expected net sales in the range of $685 million to $705 million.
Avanos Medical, Inc. is a medical device company, which is focused on delivering solutions. The Company offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Company conducts its business in one segment that provides its medical device products to healthcare providers and patients globally with manufacturing facilities in the United States and Mexico. Its digestive health products include MIC-KEY enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions. The Companyâs acute pain products include ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems. The Company's interventional pain solutions include COOLIEF pain therapy and OrthogenRxs knee osteoarthritis pain relief injection products.
AVANOS MEDICAL, INC. 
